A strategic commercialisation report for EquiEnhance, built on the Massey University School of Veterinary Science EquiFuel™ Thoroughbred trial and accompanying energy-systems model. This document sets out what the data actually shows, the size and shape of the equine performance opportunity, and a recommended commercial pathway — B2B ingredient supply as the primary route, consumer/CPG own-label as a longer-horizon option — positioned within the same PolySure™ and Four Pillar architecture already built for the human nutrition platform.
A peer-reviewed-standard pilot trial conducted by Massey University's School of Veterinary Science (Chin & Rogers) at the Ōtaki Māori Racing Club, 17–29 July 2024. This is real field data from a commercial training environment, not a laboratory simulation — which is both its strength (ecological validity) and the source of its honest limitations (small n, no washout period).
The effect scaled with intensity — the harder the horse worked, the larger the heart-rate benefit. This is the single most commercially important finding: it positions EquiEnhance specifically for high-performance/competition-intensity use, not generic feed supplementation.
The companion Massey energy-systems model (Document 2) is what elevates this from "we tried honey and horses seemed faster" to a mechanistically grounded hypothesis — and it's the document your B2B technical buyers and equine vets will actually want to see.
This is the same dual-carbohydrate, polyphenol-carrying logic that underpins LiquidFuel and LiquidGold in the human sports nutrition line. EquiEnhance is not a new scientific platform — it's the same validated bioactive honey matrix, re-dosed and re-tested for a different species. That's a genuinely powerful commercial narrative: one core science platform, multiple species-specific product expressions, each with its own clinical evidence layer. It also means formulation, supply chain, and (per Section 06) PolySure™ certification infrastructure are already built — EquiEnhance is a go-to-market and dosing exercise, not a from-scratch R&D programme.
Thoroughbred racing is one of the largest and most economically significant equestrian sports globally, and — critically for a regulated bioactive product — one of the most tightly regulated and internationally standardised, which actually works in EquiEnhance's favour.
Commercial Thoroughbred training operations — exactly the environment the Massey trial was conducted in. Buyers are trainers and stable managers who purchase feed/supplement inputs at volume, are highly receptive to evidence-backed performance claims, and operate under strict anti-doping compliance regimes (the same WADA/HASTA discipline MPL already applies to LiquidFuel/LiquidGold).
Established equine feed and supplement manufacturers (premix and finished-product) seeking differentiated, clinically-evidenced functional ingredients to incorporate into their own branded lines — the direct equivalent of MPL's existing P2 B2B ingredient buyers in human nutrition, but in an adjacent, currently under-served category.
Endurance riding, eventing, and showjumping at competitive level — disciplines with their own established carbohydrate/electrolyte supplementation culture and typically less price-sensitive owner bases than flat racing.
Both pathways are viable; they are not mutually exclusive over time. The recommendation below is sequencing, not exclusion — B2B first because it matches MPL's existing P2 playbook, requires less capital, and de-risks the category before any consumer-brand investment.
Supply EquiFuel™/EquiEnhance as a certified, evidence-backed ingredient or finished-formulation licence to established equine feed and supplement manufacturers, rather than building a standalone consumer brand from zero.
Launch EquiEnhance as a standalone, MPL-branded consumer product sold direct to trainers, stables, and competitive riders — the equine equivalent of the LiquidFuel/LiquidGold model in human nutrition.
The trial data supports a specific, disciplined marketing narrative — one built on what was actually measured, not inflated beyond it. This is also a category where overclaiming carries real regulatory and reputational risk (anti-doping compliance, veterinary scrutiny), so precision is a commercial asset, not just an ethical one.
Lead with operational simplicity and safety: zero feed refusals, zero adverse events across the trial, easy administration via evening feed. Trainers care first about "will this cause problems," and the trial answers that cleanly before any performance claim lands.
Lead with the energy-systems model and mechanistic plausibility — this audience wants to see the RER/glycogen-depletion literature and the dose-rate derivation, not just the headline result. The companion model document is the right asset to share directly with this audience.
Lead with PolySure™ certification and the platform story — that EquiEnhance is not a one-off formulation but an extension of an already-validated, ISO 17025-aligned bioactive honey matrix with a track record across human sports nutrition (LiquidFuel/LiquidGold), which de-risks their own ingredient sourcing decision.
Consistent with the Four Pillar Waterfall Strategy's flywheel logic, EquiEnhance isn't a side project — every part of it feeds back into the same data and IP assets already being built across P2, P3, and P4.
— MP Innovation Overview, Part V: Translational Innovation and Product Systems
EquiEnhance is not the end of the cross-species story. MPL's parallel work with AgResearch on a four-stage translational canine health programme (in vitro → ex vivo → in vivo → clinical, moving through cell line studies to companion-dog trials) is direct evidence the same underlying platform logic extends further.
Published literature already supports honey's anti-inflammatory potential via flavonoid content, improved haematological variables in dogs with atopic dermatitis, well-documented antimicrobial wound-healing properties, and Mānuka-specific synergy with antifungals against Malassezia pachydermatis skin infections — a strong existing evidence base the AgResearch programme is now formally extending.
Human (P1/P3 clinical trials) → Equine (Massey/EquiEnhance) → Canine (AgResearch) is a repeatable cross-species translational model, not three disconnected initiatives. Each new species validated strengthens the "platform, not product" narrative for investors and licensees, and each can share the same PolySure™ certification and Four Pillar data infrastructure — meaning the marginal cost of each new species expression keeps falling.
Sequenced so commercial activity (B2B outreach) and evidence-building (trial replication) advance in parallel rather than waiting on each other.
| Horizon | Action | Why / What It Unlocks |
|---|---|---|
| Now | Package the Massey trial report and energy-systems model into a clean technical dossier (claims-checked per Section 05) for direct use in B2B ingredient-buyer conversations. | The evidence already exists — the immediate work is translation into a sales-ready asset, not new science. |
| Now | Run EquiEnhance batches through the validated PolySure™ method to generate equine-specific CoAs. | Near-zero incremental cost given the method is already validated; immediately strengthens the B2B pitch with certified, defensible composition data. |
| Now | Approach 2–3 ANZ equine feed/supplement manufacturers for initial co-development or white-label ingredient supply conversations. | Shortest sales cycle, closest regulatory environment — the fastest realistic path to first B2B revenue. |
| Near-term | Commission a larger, multi-stable follow-on trial with Massey, incorporating blood glucose, muscle glycogen, and respiratory exchange ratio measurement as the original report recommends. | Converts "proof of concept" into a stronger, mechanistically confirmed evidence base — directly strengthens both B2B pricing power and any future consumer-brand claims. |
| Near-term | Extend B2B outreach into UK/Ireland/US/Gulf premium racing markets, leveraging the international consistency of Thoroughbred racing regulation. | Larger, higher-value stables with strong willingness to pay for evidence-backed performance edges. |
| Near-term | Explore co-marketing or bundled positioning between EquiEnhance and the emerging canine health platform under a shared "Bioactive Honey Matrix — validated across species" narrative. | Reinforces the platform story to investors and licensees at minimal incremental marketing cost. |
| Far-term | Evaluate a standalone EquiEnhance consumer brand launch, funded and de-risked by accumulated B2B revenue and expanded trial evidence. | Captures the higher long-run margin and full brand equity of the CPG pathway, once category risk is substantially reduced. |
| Far-term | Formalise equine performance data (dose-response, intensity-scaling, individual variation) as a distinct axis within the broader Pillar 4 bioactive intelligence database. | Extends the "growing phytochemical database" asset described in the Pillar 4 report into a genuinely multi-species dataset — a meaningfully harder asset for competitors to replicate. |